Clinical Trial Update: PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating PSMA-PET/CT to assess PSMA expression in patients with progressive triple-negative breast cancer; recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Jules Bordet Institute | Conditions: TNBC - Triple-Negative Breast Cancer | Phase 2 | Status: RECRUITING